Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients

被引：18

作者：

Owosho, Adepitan A. ^{[1
]}

Blanchard, Ariel ^{[1
]}

Levi, Lauren ^{[1
]}

Kadempour, Arvin ^{[1
]}

Rosenberg, Haley ^{[1
]}

Yom, SaeHee K. ^{[1
]}

Farooki, Azeez ^{[2
]}

Fornier, Monica ^{[2
]}

Huryn, Joseph M. ^{[1
]}

Estilo, Cherry L. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA

来源：

JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY | 2016年 / 44卷 / 03期

关键词：

Denosumab; Osteonecrosis of the jaw; Metastatic bone disease; BISPHOSPHONATE-RELATED OSTEONECROSIS; MEDICATION-RELATED OSTEONECROSIS; SKELETAL-RELATED EVENTS; ZOLEDRONIC ACID; BREAST-CANCER; RISK-FACTORS; MULTIPLE-MYELOMA; COST-EFFECTIVENESS; PROSTATE-CANCER; DOUBLE-BLIND;

D O I：

10.1016/j.jcms.2015.12.005

中图分类号：

R78 [口腔科学];

学科分类号：

1003 ;

摘要：

This case series describes the course of osteonecrosis of the jaw (ONJ) in thirteen patients with metastatic bone tumors treated solely with denosumab. Patients on denosumab may be more prone to developing ONJ even without a risk/precipitating factor and they may develop ONJ early in their denosumab therapy. The outcomes of ONJ in ten patients following a period of denosumab discontinuation after the onset of ONJ were: 3 had complete resolution of symptoms, 4 patients' ONJ progressed, 2 patients' ONJ was unchanged and in 1 patient there was partial ONJ resolution. The role of drug discontinuation prior to an invasive dental procedure or after the onset of ONJ still remains debatable. (C) 2015 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

引用

页码：265 / 270

页数：6

共 60 条

[1] Osteonecrosis of the Jaw in a Patient on Denosumab [J].

Aghaloo, Tara L. ;

Felsenfeld, Alan L. ;

Tetradis, Sotirios .

JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2010, 68 (05) :959-963

[2] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].

Bamias, A ;

Kastritis, E ;

Bamia, C ;

Moulopoulos, LA ;

Melakopoulos, L ;

Bozas, G ;

Koutsoukou, V ;

Gika, D ;

Anagnostopoulos, A ;

Papadimitriou, C ;

Terpos, E ;

Dimopoulos, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587

[3] Denosumab and bisphosphonates: Different mechanisms of action and effects [J].

Baron, Roland ;

Ferrari, Serge ;

Russell, R. Graham G. .

BONE, 2011, 48 (04) :677-692

[4] Osteoclast differentiation and activation [J].

Boyle, WJ ;

Simonet, WS ;

Lacey, DL .

NATURE, 2003, 423 (6937) :337-342

[5] Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid [J].

Cetiner, Sedat ;

Sucak, Gulsan Turkoz ;

Kahraman, Sevil Altundag ;

Aki, Sahika Zeynep ;

Kocakahyaoglu, Benay ;

Gultekin, Sibel Elif ;

Cetiner, Mustafa ;

Haznedar, Rauf .

JOURNAL OF BONE AND MINERAL METABOLISM, 2009, 27 (04) :435-443

[6] Metastatic bone disease: clinical features, pathophysiology and treatment strategies [J].

Coleman, RE .

CANCER TREATMENT REVIEWS, 2001, 27 (03) :165-176

[7] Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis [J].

Cummings, Steven R. ;

San Martin, Javier ;

McClung, Michael R. ;

Siris, Ethel S. ;

Eastell, Richard ;

Reid, Ian R. ;

Delmas, Pierre ;

Zoog, Holly B. ;

Austin, Matt ;

Wang, Andrea ;

Kutilek, Stepan ;

Adami, Silvano ;

Zanchetta, Jose ;

Libanati, Cesar ;

Siddhanti, Suresh ;

Christiansen, Claus .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :756-765

[8]

Damm Douglas D., 2013, General Dentistry, V61, P33

[9]

Dimopoulos MA, 2006, HAEMATOL-HEMATOL J, V91, P968

[10] Denosumab-related osteonecrosis of the jaw [J].

Diz, Pedro ;

Luis Lopez-Cedrun, Jose ;

Arenaz, Jorge ;

Scully, Crispian .

JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 2012, 143 (09) :981-984

← 1 2 3 4 5 6 →